|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TABLE 1 Baseline characteristics Dutch LATER cohort. | | |  | |  | |  | |  |
| **Characteristics** | **Underlying cohort (n=6,165)** | | **invited study population  (n=4,735)  (76.8% of underlying cohort)** | | **Participants (n=2,519)  (53.2% of the invited population)** | | **Non-participants (n=2,216)  (46.8% of the invited population)** | | **P-value participants vs non participants** |
|  | n | % | n | % | n | % | n | % |  |
| *Sex* |  |  |  |  |  |  |  |  | p<0.00001 |
| Female | 2731 | 44,3% | 2092 | 44,2% | 1242 | 49,3% | 850 | 38,4% |  |
| Male | 3433 | 55,7% | 2643 | 55,8% | 1277 | 50,7% | 1365 | 61,6% |  |
| Transgender | 1 | 0,01% | 0 | 0,0% | 0 | 0,0% | 1 | 0,05% |  |
| *Primary childhood cancer (ICCC)* |  |  |  |  |  |  |  |  | p<0.00001 |
| Leukemias, myeloprofiferative diseases and myelodysplastic diseases | 2094 | 34,0% | 1631 | 34,4% | 897 | 35,6% | 734 | 33,1% | p=0.07 |
| Lymphomas and reticulo endothelial neoplasms | 1062 | 17,2% | 865 | 18,3% | 477 | 18,9% | 388 | 17,5% | p=0.21 |
| CNS and miscellaneous intracranial and intraspinal neoplasms | 844 | 13,7% | 560 | 11,8% | 232 | 9,2% | 328 | 14,8% | p<0.00001 |
| Neuroblastoma and other peripheral nervous cell tumors | 324 | 5,3% | 256 | 5,4% | 151 | 6,0% | 105 | 4,7% | p=0.06 |
| Retinoblastoma | 33 | 0,5% | 26 | 0,5% | 11 | 0,4% | 15 | 0,7% | p=0.26 |
| Renal tumors | 596 | 9,7% | 497 | 10,5% | 284 | 11,3% | 213 | 9,6% | p=0.06 |
| Hepatic tumors | 52 | 0,8% | 48 | 1,0% | 21 | 0,8% | 27 | 1,2% | p=0.19 |
| Bone tumors | 370 | 6,0% | 262 | 5,5% | 139 | 5,5% | 123 | 5,6% | p=0.96 |
| Soft tissue and other extraosseous sarcomas | 450 | 7,3% | 339 | 7,2% | 181 | 7,2% | 158 | 7,1% | p=0.94 |
| Germ cell tumors, trophoblastic tumors, and neoplasms of gonads | 232 | 3,8% | 180 | 3,8% | 90 | 3,6% | 90 | 4,1% | p=0.39 |
| Other malignant epithelial neoplasms and malignant melanomas | 102 | 1,7% | 66 | 1,4% | 32 | 1,3% | 34 | 1,5% | p=0.44 |
| Other and unspecified malignant neoplasms | 6 | 0,1% | 5 | 0,1% | 4 | 0,2% | 1 | 0,0% | p=0.23 |
| *Age at diagnosis (yr)* | *5,6* | *0-17,9* |  |  | *5,4* | *0-17,4* | *5,4* | *0-17,7* | p=0.80 |
| 0-4 | 2727 | 44,2% | 2208 | 46,6% | 1184 | 47,0% | 1024 | 46,2% |  |
| 5-9 | 1628 | 26,4% | 1281 | 27,1% | 677 | 26,9% | 604 | 27,3% |  |
| 10-14 | 1285 | 20,8% | 970 | 20,5% | 508 | 20,2% | 462 | 20,8% |  |
| 15-17 | 376 | 6,1% | 271 | 5,7% | 150 | 6,0% | 121 | 5,5% |  |
| *Treatment period* |  |  |  |  |  |  |  |  | p=0.51 |
| 1963-1969 | 119 | 1,9% | 67 | 1,4% | 35 | 1,4% | 32 | 1,4% |  |
| 1970-1979 | 978 | 15,9% | 628 | 13,3% | 336 | 13,3% | 292 | 13,2% |  |
| 1980-1989 | 1931 | 31,3% | 1454 | 30,7% | 781 | 31,0% | 673 | 30,4% |  |
| 1990-2001 | 3137 | 50,9% | 2586 | 54,6% | 1367 | 54,3% | 1291 | 58,3% |  |
| *Age at invitation* |  |  |  |  | *34,2* | *15,5-65,4* | *34,4* | *15,4-66,6* | p=0.35 |
| <18 | - | - | 49 | 1,0% | 36 | 1,4% | 13 | 0,6% |  |
| 18-30 | - | - | 1313 | 27,7% | 821 | 32,6% | 492 | 22,2% |  |
| 30-40 | - | - | 1511 | 31,9% | 944 | 37,5% | 567 | 25,6% |  |
| >40 | - | - | 1118 | 23,6% | 718 | 28,5% | 400 | 18,1% |  |
| *Follow-up time since childhood cancer diagnosis to invitation* |  |  |  |  | 26,9 | 14,8-54,7 | 26,8 | 13,2-55,9 | p=0.53 |
| 10-20 | - | - | 696 | 14,7% | 531 | 21,1% | 438 | 19,8% |  |
| 20-30 | - | - | 1896 | 40,0% | 989 | 39,3% | 907 | 40,9% |  |
| 30-40 | - | - | 1373 | 29,0% | 741 | 29,4% | 632 | 28,5% |  |
| 40-50 | - | - | 452 | 9,5% | 232 | 9,2% | 220 | 9,9% |  |
| 50-60 | - | - | 45 | 1,0% | 26 | 1,0% | 19 | 0,9% |  |
| *Chemotherapya* |  |  |  |  |  |  |  |  | p<0.00001 |
| No | 1123 | 18,2% | 793 | 16,7% | 309 | 12,3% | 484 | 21,8% |  |
| Yes | 5005 | 81,2% | 3935 | 83,1% | 2210 | 87,7% | 1725 | 77,8% |  |
| Missing | 37 | 0,6% | 7 | 0,1% | 0 | 0,0% | 7 | 0,3% |  |
| *Radiotherapya* |  |  |  |  |  |  |  |  | p=0.0002 |
| No | 3608 | 58,5% | 3026 | 63,9% | 1551 | 61,6% | 1475 | 66,6% |  |
| Yes | 2527 | 41,0% | 1701 | 35,9% | 967 | 38,4% | 734 | 33,1% |  |
| Missing | 30 | 0,5% | 8 | 0,2% | 1 | 0,0% | 7 | 0,3% |  |
| *Surgerya* |  |  |  |  |  |  |  |  | p=0.008 |
| No | 2912 | 47,2% | 2316 | 48,9% | 1280 | 50,8% | 1036 | 46,8% |  |
| Yes | 3185 | 51,7% | 2396 | 50,6% | 1232 | 48,9% | 1164 | 52,5% |  |
| Missing | 68 | 1,1% | 23 | 0,5% | 7 | 0,3% | 16 | 0,7% |  |
| *Hematopoietic cell transplantion a,b* |  |  |  |  |  |  |  |  | p=0.0005 |
| No | 5532 | 92,0% | 4445 | 93,9% | 2337 | 92,8% | 2108 | 95,1% |  |
| Autologous transplant | 155 | 2,6% | 91 | 1,9% | 57 | 2,3% | 34 | 1,5% |  |
| Allogenic transplant | 231 | 3,8% | 161 | 3,4% | 109 | 4,3% | 52 | 2,3% |  |
| Missing | 98 | 1,6% | 33 | 0,7% | 16 | 0,6% | 17 | 0,8% |  |
| *Therapy* |  |  |  |  |  |  |  |  | p<0.00001 |
| No treatment | 61 | 1,0% | 39 | 0,8% | 13 | 0,5% | 26 | 1,2% | p=0.012 |
| Surgery only | 575 | 9,3% | 453 | 9,6% | 163 | 6,5% | 290 | 13,1% | p<0.00001 |
| Chemotherapy only (± surgery) | 2967 | 48,1% | 2533 | 53,5% | 1375 | 54,6% | 1158 | 52,3% | p=0.007 |
| Radiotherapy only (± surgery) | 484 | 7,9% | 300 | 6,3% | 133 | 5,3% | 167 | 7,5% | p=0.001 |
| Chemotherapy and radiotherapy (± surgery) | 2030 | 32,9% | 1400 | 29,6% | 834 | 33,1% | 566 | 25,5% | p<0.00001 |
| Missing | 48 | 0,8% | 10 | 0,2% | 1 | 0,0% | 9 | 0,4% | p=0,006 |
| a For primary cancer and recurrences |  |  |  |  |  |  |  |  |  |
| b Only for n=6,016 CCS (all survivors who did not decline registration in the DCCSS LATER database) | | | | | | | | | |